Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology
Three Years On, Strategy Under CEO O’Day Is Unchanged
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.
You may also be interested in...
ViiV’s Bid To Switch HIV Patients To Cabenuva Boosted By Biktarvy Head-To-Head
A new head-to-head proves Cabenuva is a match for Gilead’s Biktarvy, which should boost uptake of the long-acting HIV treatment.
Gilead’s Trodelvy Basks In TROPiCS With FDA Breast Cancer Nod
Gilead’s big push into oncology bore more fruit with the FDA approval of Trodelvy based on the TROPiCS-02 trial. More development catalysts lie ahead for 2023, company said in its earnings.
Gilead CAR-T Joins Billion-Dollar Club As Biktarvy Sales Cross $10bn Mark
Yescarta surged ahead of competitors Kymriah and Breyanzi, helping Gilead’s oncology sales exceed $2bn, while the company reported the strongest sales in its HIV-dominated core business since 2015.